A phase II trial of induction chemotherapy followed by continuous hyperfractionated accelerated radiotherapy in locally advanced non-small-cell lung cancer

Radiotherapy and Oncology

Volumn 93, Issue 3, 2009, Pages 396-401

  Jenkins, Peter ^a   Anderson, Susan ^a   Wronski, Susan ^a   Ashton, Anita ^a  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

Accelerated radiotherapy; CHART; Chemoradiation; Lung cancer

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; MITOMYCIN C; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS HYPERFRACTIONATED ACCELERATED RADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION PNEUMONIA; RADIATION SICKNESS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; SURVIVAL RATE; VINBLASTINE;

EID: 70449657771     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.04.002     Document Type: Article

References (30)

1. Dillman R.O., Seagren S.L., Propert K.J., et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323 (1990) 940-945
2. Le Chevalier T., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83 (1991) 417-423
3. Sause W.T., Scott C., Taylor S., et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87 (1995) 198-205
4. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (1992) 524-530
5. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
6. Curran W.J., Scott C.B., Langer C.J., et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22 (2003) 2499
7. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46 (2004) 87-98
8. Fournel P., Robinet G., Thomas P., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23 (2005) 5910-5917
9. Machtay M., Hsu C., Komaki R., et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 63 (2005) 667-671
10. De Ruysscher D., Pijls-Johannesma M., Bentzen S.M., et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24 (2006) 1057-1063
11. Davis A.J., and Tannock J.F. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 1 (2000) 86-93
12. Bentzen S.M. Repopulation in radiation oncology: perspectives of clinical research. Int J Radiat Biol 79 (2003) 581-585
13. Saunders M., Dische S., Barrett A., Harvey A., Griffiths G., and Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. Radiother Oncol 52 (1999) 137-148
14. Jenkins P., Milliner R., and Latimer P. Shrinkage of locally advanced non-small-cell lung cancers in response to induction chemotherapy: implications for radiotherapy treatment planning. Int J Radiat Oncol Biol Phys 69 (2007) 993-1000
15. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
16. Bartelink H., Schellens J.H., and Verheij M. The combined use of radiotherapy and chemotherapy in the treatment of solid tumours. Eur J Cancer 38 (2002) 216-222
17. El Sharouni S.Y., Kal H.B., and Battermann J.J. Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy. Br J Cancer 89 (2003) 2184-2189
18. Turrisi III A.T., Kim K., Blum R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 (1999) 265-271
19. Oral E.N., Bavbek S., Kizir A., et al. Preliminary analysis of a phase II study of paclitaxel and CHART in locally advanced non-small cell lung cancer. Lung Cancer 25 (1999) 191-198
20. Oner Dincbas F., Koca S., Altinel A., et al. Continuous accelerated hyperfractionated radiotherapy (CHART) plus chemotherapy (CT) with vinorelbine (VB) and cisplatinum (CDDP) in locally advanced NSCLC (TOG-011 study). Eur J Cancer 37 (2001) S53
21. Kirkbride P., Hatton M., Lorigan P., Joyce P., and Fisher P. Fatal pulmonary fibrosis associated with induction chemotherapy with carboplatin and vinorelbine followed by CHART radiotherapy for locally advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) 14 (2002) 361-366
22. Albain K.S., Swann R.S., Rusch V., et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 23 (2005) 7014
23. Auperin A., Rolland E., Curran W., et al. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer: a meta-analysis using individual patient data from randomised clinical trials. J Thoracic Oncol 2 (2007) S310
24. Werner-Wasik M., Scott C., Cox J.D., et al. Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48 (2000) 1475-1482
25. Belderbos J., Uitterhoeve L., van Zandwijk N., et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur J Cancer 43 (2007) 114-121
26. Belani C.P., Wang W., Johnson D.H., et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 23 (2005) 3760-3767
27. Bonomi M., Blanco-Savorio A., Cerchietti L., et al. Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer. Lung Cancer 60 (2008) 75-82
28. Ishikura S., Ohe Y., Nihei K., et al. A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 61 (2005) 1117-1122
29. Chen G.Y., Jiang G.L., Qian H., et al. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial. Radiother Oncol 71 (2004) 157-162
30. Rojas A.M., Lyn B.E., Wilson E.M., et al. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer. Cancer 107 (2006) 1321-1330